/C O R R E C T I O N -- TC BioPharm/
TC BioPharm (NASDAQ: TCBP) has announced and received shareholder approval for a 25% stock dividend. Shareholders will receive 0.25 American Depositary Shares (ADSs) for every 1 ADS held as of the record date of January 2, 2025. The distribution is expected to occur on or about January 6th, 2025.
Trading of TCBP's ADSs will temporarily halt at 5:00 pm on January 2, 2025, and resume on January 7, 2025, allowing the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 7 to account for the dilution impact.
CEO Bryan Kobel emphasized that this special dividend demonstrates management's confidence in the company's financial future and serves as a component of their capital management strategy. He expressed optimism about 2025 being a period of growth and development for the clinical-stage biotechnology company, which develops platform allogeneic gamma-delta T cell therapies for cancer and other indications.
TC BioPharm (NASDAQ: TCBP) ha annunciato e ricevuto l'approvazione degli azionisti per un dividendo azionario del 25%. Gli azionisti riceveranno 0,25 Azioni di Deposito Americane (ADS) per ogni 1 ADS detenuta alla data di registrazione del 2 gennaio 2025. La distribuzione dovrebbe avvenire il 6 gennaio 2025 o circa.
Le negoziazioni delle ADS di TCBP si fermeranno temporaneamente alle 17:00 del 2 gennaio 2025 e riprenderanno il 7 gennaio 2025, consentendo al Depositary di elaborare il dividendo azionario. Il Nasdaq regolerà il prezzo di apertura il 7 gennaio per tenere conto dell'impatto della diluizione.
Il CEO Bryan Kobel ha sottolineato che questo dividendo speciale dimostra la fiducia della direzione nel futuro finanziario dell'azienda e costituisce un elemento della loro strategia di gestione del capitale. Ha espresso ottimismo riguardo al 2025 come un periodo di crescita e sviluppo per l'azienda biotecnologica in fase clinica, che sviluppa terapie allogeniche con cellule T gamma-delta per il cancro e altre indicazioni.
TC BioPharm (NASDAQ: TCBP) ha anunciado y recibido la aprobación de los accionistas para un dividendo de acciones del 25%. Los accionistas recibirán 0,25 Acciones de Depósito Americanas (ADS) por cada 1 ADS en posesión a partir de la fecha de registro del 2 de enero de 2025. Se espera que la distribución ocurra el 6 de enero de 2025 o alrededor de esa fecha.
La negociación de las ADS de TCBP se detendrá temporalmente a las 5:00 p.m. del 2 de enero de 2025 y se reanudará el 7 de enero de 2025, lo que permitirá al Depositary procesar el dividendo de acciones. Nasdaq ajustará el precio de apertura el 7 de enero para tener en cuenta el impacto de la dilución.
El CEO Bryan Kobel enfatizó que este dividendo especial demuestra la confianza de la dirección en el futuro financiero de la empresa y forma parte de su estrategia de gestión de capital. Expresó optimismo sobre que 2025 será un período de crecimiento y desarrollo para la empresa biotecnológica en etapa clínica, que desarrolla terapias alogénicas de células T gamma-delta para el cáncer y otras indicaciones.
TC BioPharm (NASDAQ: TCBP)는 25%의 주식 배당금을 발표하고 주주 승인을 받았습니다. 주주들은 2025년 1월 2일 기준으로 보유한 1 ADS당 0.25개의 미국 예탁 주식(ADS)을 받게 됩니다. 배당금 분배는 2025년 1월 6일 또는 그 전후에 이루어질 것으로 예상됩니다.
TCBP의 ADS 거래는 2025년 1월 2일 오후 5시부터 일시 중단되며, 2025년 1월 7일에 재개되어 예탁기관이 주식 배당금을 처리할 시간 여유를 줍니다. 나스닥은 희석 효과를 반영하기 위해 1월 7일 개장 가격을 조정할 것입니다.
CEO 브라이언 코벨은 이번 특별 배당금이 회사의 재무 미래에 대한 경영진의 신뢰를 보여주며, 자본 관리 전략의 한 요소임을 강조했습니다. 그는 2025년이 임상 단계의 생명공학 회사가 암 및 기타 적응증을 위한 알로겐성 감마 델타 T 세포 요법을 개발하는 성장과 발전의 시기가 될 것이라고 낙관했습니다.
TC BioPharm (NASDAQ: TCBP) a annoncé et reçu l'approbation des actionnaires pour un dividende en actions de 25%. Les actionnaires recevront 0,25 Actions de Dépôt Américaines (ADS) pour chaque 1 ADS détenue à la date d'enregistrement du 2 janvier 2025. La distribution devrait avoir lieu le 6 janvier 2025 ou vers cette date.
Les échanges des ADS de TCBP seront temporairement suspendus à 17h00 le 2 janvier 2025 et reprendront le 7 janvier 2025, permettant au Dépositaire de traiter le dividende en actions. Nasdaq ajustera le prix d'ouverture du 7 janvier pour tenir compte de l'impact de la dilution.
Le PDG Bryan Kobel a souligné que ce dividende spécial démontre la confiance de la direction dans l'avenir financier de l'entreprise et constitue un élément de leur stratégie de gestion des capitaux. Il a exprimé son optimisme quant au fait que 2025 sera une période de croissance et de développement pour l'entreprise biopharmaceutique en phase clinique, qui développe des thérapies cellulaires γ-delta T allogènes pour le cancer et d'autres indications.
TC BioPharm (NASDAQ: TCBP) hat einen 25% Aktiendividende angekündigt und die Genehmigung der Aktionäre erhalten. Aktionäre erhalten für jede gehaltene 1 ADS am 2. Januar 2025 0,25 Amerikanische Depot-Aktien (ADS). Die Verteilung wird voraussichtlich am 6. Januar 2025 oder um diesen Zeitpunkt erfolgen.
Der Handel mit TCBP's ADS wird am 2. Januar 2025 um 17:00 Uhr vorübergehend ausgesetzt und am 7. Januar 2025 wieder aufgenommen, um dem Depot die Verarbeitung der Aktiendividende zu ermöglichen. Die Nasdaq wird den Eröffnungspreis am 7. Januar anpassen, um den Verwässerungseffekt zu berücksichtigen.
CEO Bryan Kobel betonte, dass diese Sonderdividende das Vertrauen des Managements in die finanzielle Zukunft des Unternehmens zeigt und ein Bestandteil ihrer Kapitalmanagementstrategie ist. Er äußerte Optimismus, dass 2025 eine Wachstums- und Entwicklungsperiode für das biotechnologische Unternehmen in der klinischen Phase sein wird, das allelenogene Gamma-Delta-T-Zelltherapien für Krebs und andere Indikationen entwickelt.
- None.
- None.
In the news release, TCBP Issues
TCBP Issues 25% Stock Dividend
Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company. The special dividend of 0.25 American Depositary Shares ("ADSs") for every 1 ADS held by shareholders on the record date of January 2, 2025 are expected to be delivered to shareholders on or about January 6th.
TC BioPharm CEO, Bryan Kobel stated: "Rewarding additional shares to shareholders in the form of this special dividend is an important and effective component of our capital management strategy. It also reflects management's strong confidence in the Company's financial future. I anticipate 2025 to be a period of growth and development for our Company as we remain focused on delivering improved value for our shareholders."
Per Nasdaq requirements, trading in the Company's ADSs will temporarily stop at 5:00 pm on January 2, 2025, and recommence on or around January 7, 2025, to allow the Depositary to process the stock dividend. Nasdaq will adjust the opening price on January 7 to reflect the dilution impact of the stock dividend.
This press release is for informational purposes only. It shall not constitute an offer to sell or exchange nor the solicitation of an offer to buy shares of the Company's common stock or any other securities. For additional information regarding TC BioPharm's General Meeting see our website and filings to be made on form 6K.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T-cell therapies for cancer treatment with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tcbp-issues-25-stock-dividend-302340235.html
SOURCE TC BioPharm
FAQ
What is the percentage of TCBP's stock dividend announced for January 2025?
When will TCBP shareholders receive their stock dividend in January 2025?
How long will TCBP stock trading be halted for the dividend distribution?
What impact will the stock dividend have on TCBP's trading price?
What is the record date for TCBP's 2025 stock dividend?
